Drug Database
Back to search

Netherlands· NL-132f7a855b93

Ebglyss 250 mg oplossing voor injectie in voorgevulde pen

A lebrikizumab product containing lebrikizumab, registered in Netherlands by Grupo Farmacéutico Almirall S.A.. The same ATC class is registered in 15 of our 19 countries.

ATC D11AH10

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEbglyss 250 mg oplossing voor injecti…ATCD11AH10REGISTER NO.NL-132f7a855b93PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lebrikizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lebrikizumab is registered in 15 of 19 countries.

Countries holding a registration under ATC D11AH10 (lebrikizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search lebrikizumab products by name

Lebrikizumab · ATC D11AH10

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lebrikizumab costs, country by country.

Normalised to the WHO defined daily dose (8.9 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lebrikizumab · price per daily dose (8.9 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$20.32
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LEBRIKIZUMAB
Manufacturer
Grupo Farmacéutico Almirall S.A.
Country
Netherlands (NL)
ATC code
D11AH10
ATC class
Lebrikizumab
Defined daily dose
8.9 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1765

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lebrikizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lebrikizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ebglyss
  • Liechtenstein · Ebglyss
  • Norway · Ebglyss

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3ea83f79-95be-41e7-b562-1a1b7ca431e0
GET /v1/drugs/3ea83f79-95be-41e7-b562-1a1b7ca431e0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ebglyss-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lebrikizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130621",
  "excipients": [
    "AZIJNZUUR (E 260)",
    "HISTIDINE, (L-)",
    "POLYSORBAAT 20 (E 432)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "LEBRIKIZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/11/16",
  "procedure_number": "EMEA/H/C/005894",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1765",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about lebrikizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console